Apurinic/Apyrimidinic Endonuclease 1/Redox Effector- 1 (APE1/Ref-1) is a negative regulator of inflammatory response via several mechanisms in neuronal cells. APE1’s redox activity stimulates the DNA-binding activity of several transcription factors. We investigated targeting the APE1 redox activity that might influence the neurotransmitters and related receptors by intradermal injection of E3330 (selective redox inhibitor of APE1) in formalin- induced rat inflammatory pain model. Accumulating evidence has shown that dopamine systems in the brain are also involved in the central regulation of chronic pain. Most importantly, descending dopaminergic pathways play an important role in pain modulation. Therefore, we tested the effect of APE1 redox activity on the regulation of dopaminergic signaling pathway. We determined the index of pain through behavioral tests after peripheral induction of formalin (50µl in the dorsal surface of hindpaw). Interestingly, our data point to a decreased nuclear accumulation of APE1 mRNA expression, changed its distribution in the inflamed group as compared to the sham group (i.e. reduced IL-6 expression) and alleviated pain, as assessed by measuring the paw edema. In support to our results, the study of Pacheco, 2017 reported that high-dopamine levels promote the stimulation of low affinity dopamine receptors including, DRD1, DRD2 and DRD4, inducing anti-inflammatory effect in microglia, while low dopamine levels selectively stimulate high-affinity dopamine receptors including, DRD3 and DRD5, triggering inflammation. In conclusion, inhibition of the Redox function by E3330 compound might constitute a novel approach for treating inflammatory pain through modulating the level of dopamine and the affinity of its D5R and D2R receptors inside spinal cord.